Monday, July 26


Aduhelm, Alzheimer's Disease, biogen, Dispensed, FDA, Healthcare

The head of the FDA is calling for an investigation into her agency’s controversial decision to approve a new Alzheimer’s drug

Interim FDA Commissioner Janet Woodcock has asked for an outside investigation into an Alzheimer's drug approval. The agency approved the drug, Aduhelm, last month, despite a lack of evidence showing the drug slowed the disease. Officials from Biogen and the FDA worked closely together to revive the drug, raising concerns. LoadingSomething is loading. ...